About
Arthrosi is a clinical-stage biotechnology company developing AR882, a novel therapy aimed at lowering urate levels and treating gout patients with renal impairment, as well as chronic kidney disease.
Explore Arthrosi's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.